LIM-domain-only 4 (LMO4) enhances CD8⁺ T-cell stemness and tumor rejection by boosting IL-21-STAT3 signaling.

Autor: Schelker, Roland C., Fioravanti, Jessica, Mastrogiovanni, Fabio, Baldwin, Jeremy G., Rana, Nisha, Li, Peng, Chen, Ping, Vadász, Timea, Spolski, Rosanne, Heuser-Loy, Christoph, Slavkovic-Lukic, Dragana, Noronha, Pedro, Damiano, Giuseppe, Raccosta, Laura, Maggioni, Daniela, Pullugula, Sree, Lin, Jian-Xin, Oh, Jangsuk, Grandinetti, Patrick, Lecce, Mario

Publikováno v: Signal Transduction & Targeted Therapy; 8/9/2024, Vol. 9 Issue 1, p1-13, 13p

Identification of two distinct hereditary hemorrhagic telangiectasia patient subsets with different hepatic perfusion properties by combination of contrast-enhanced ultrasound (CEUS) with perfusion imaging quantification.

Autor: Schelker, Roland C.¹ roland.schelker@ukr.de, Andorfer, Kornelia², Putz, Franz³, Herr, Wolfgang¹, Jung, Ernst-Michael⁴

Publikováno v: PLoS ONE. 4/12/2019, Vol. 14 Issue 4, p1-13. 13p.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Intercellular nanotube-mediated mitochondrial transfer enhances T cell metabolic fitness and antitumor efficacy.

Autor: Baldwin JG; Division of Functional Immune Cell Modulation, Leibniz Institute for Immunotherapy, Regensburg, Germany; Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. Electronic address: jeremy.baldwin@ukr.de., Heuser-Loy C; Division of Functional Immune Cell Modulation, Leibniz Institute for Immunotherapy, Regensburg, Germany., Saha T; Center for Engineered Therapeutics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; Harvard-MIT Division of Health Sciences and Technology, Cambridge, MA, USA., Schelker RC; Division of Functional Immune Cell Modulation, Leibniz Institute for Immunotherapy, Regensburg, Germany; Department of Internal Medicine III, University Hospital Regensburg, Regensburg, Germany., Slavkovic-Lukic D; Division of Functional Immune Cell Modulation, Leibniz Institute for Immunotherapy, Regensburg, Germany., Strieder N; Next Generation Sequencing Core, Leibniz Institute for Immunotherapy, Regensburg, Germany., Hernandez-Lopez I; Next Generation Sequencing Core, Leibniz Institute for Immunotherapy, Regensburg, Germany., Rana N; Division of Functional Immune Cell Modulation, Leibniz Institute for Immunotherapy, Regensburg, Germany; University of Regensburg, Regensburg, Germany., Barden M; Division of Genetic Immunotherapy, Leibniz Institute for Immunotherapy, Regensburg, Germany., Mastrogiovanni F; Division of Functional Immune Cell Modulation, Leibniz Institute for Immunotherapy, Regensburg, Germany., Martín-Santos A; Division of Functional Immune Cell Modulation, Leibniz Institute for Immunotherapy, Regensburg, Germany., Raimondi A; Experimental Imaging Centre, IRCCS San Raffaele Scientific Institute, Milan, Italy., Brohawn P; Translational Science and Experimental Medicine, Early R&I, AstraZeneca, Gaithersburg, MD, USA., Higgs BW; Genmab, Princeton, NJ, USA., Gebhard C; Next Generation Sequencing Core, Leibniz Institute for Immunotherapy, Regensburg, Germany., Kapoor V; Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Telford WG; Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Gautam S; Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Xydia M; Bavarian Cancer Research Center (BZKF), Regensburg, Germany; Division of Interventional Immunology, Leibniz Institute for Immunotherapy, Regensburg, Germany., Beckhove P; Department of Internal Medicine III, University Hospital Regensburg, Regensburg, Germany; University of Regensburg, Regensburg, Germany; Division of Interventional Immunology, Leibniz Institute for Immunotherapy, Regensburg, Germany., Frischholz S; Mikrobiologisches Institut, Klinische Mikrobiologie, Immunologie und Hygiene, Universitätsklinikum Erlangen und Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg, Erlangen, Germany., Schober K; Mikrobiologisches Institut, Klinische Mikrobiologie, Immunologie und Hygiene, Universitätsklinikum Erlangen und Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg, Erlangen, Germany; FAU Profile Center Immunomedicine, FAU Erlangen-Nürnberg, Erlangen, Germany., Kontarakis Z; Genome Engineering and Measurement Laboratory (GEML), ETH Zürich, Zürich, Switzerland; Functional Genomics Center Zürich, ETH Zürich, University of Zürich, Zürich 8057, Switzerland., Corn JE; Department of Biology, Institute of Molecular Health Sciences, ETH Zürich, Zürich, Switzerland., Iannacone M; Division of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy., Inverso D; Division of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy., Rehli M; Department of Internal Medicine III, University Hospital Regensburg, Regensburg, Germany; Next Generation Sequencing Core, Leibniz Institute for Immunotherapy, Regensburg, Germany., Fioravanti J; Division of Functional Immune Cell Modulation, Leibniz Institute for Immunotherapy, Regensburg, Germany; Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Sengupta S; Center for Engineered Therapeutics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; Harvard-MIT Division of Health Sciences and Technology, Cambridge, MA, USA. Electronic address: shiladit@mit.edu., Gattinoni L; Division of Functional Immune Cell Modulation, Leibniz Institute for Immunotherapy, Regensburg, Germany; Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA; University of Regensburg, Regensburg, Germany; Center for Immunomedicine in Transplantation and Oncology, University Hospital Regensburg, Regensburg, Germany. Electronic address: luca.gattinoni@lit.eu.

Publikováno v: Cell [Cell] 2024 Sep 12. Date of Electronic Publication: 2024 Sep 12.